| Autor: |
Kuguyo O; University of Zimbabwe College of Health Sciences, Department of Clinical Pharmacology, Avondale, Harare, Zimbabwe.; University of Cape Town, Faculty of Health Sciences Department of Pathology, Human Genetics Division, 1 Anzio Rd, Observatory, Cape Town, South Africa., Tsikai N; of Zimbabwe College of Health Sciences, Department of Oncology, Avondale, Harare, Zimbabwe., Muradzikwa SC; University of Witwatersrand, Department of Statistics, Johannesburg, South Africa., Mhandire K; University of Cape Town, Faculty of Health Sciences Department of Pathology, Human Genetics Division, 1 Anzio Rd, Observatory, Cape Town, South Africa., Nhachi C; University of Zimbabwe College of Health Sciences, Department of Clinical Pharmacology, Avondale, Harare, Zimbabwe., Magwali T; University of Zimbabwe College of Health Sciences, Department of Obstetrics and Gynaecology, Avondale, Harare, Zimbabwe., Madziyire MG; University of Zimbabwe College of Health Sciences, Department of Obstetrics and Gynaecology, Avondale, Harare, Zimbabwe., Matimba A; Advanced Courses and Scientific Conferences, Wellcome Genome Campus, Hinxton, UK., Dandara C; University of Cape Town, Faculty of Health Sciences Department of Pathology, Human Genetics Division, 1 Anzio Rd, Observatory, Cape Town, South Africa.; Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa. |
| Abstrakt: |
Cervical cancer is the leading cause of cancer deaths in women in Africa, predominately due to late diagnosis. This study aims to identify risk factors, potential prognostic indicators, and optimal treatment modalities for Zimbabwean cervical cancer patients. Medical records for 1063 cervical cancer patients were reviewed for sociodemographic, clinical, treatment, and response data. All data were analysed using SPSS version 25. More than half of the cohort was pre-menopausal (63%) with low (2%) history of cervical cancer screening. Schistosoma ova were observed in 2.4% of the tumour specimens. More than 50% were diagnosed at stage 3 and later, with a high frequency of comorbidities (~68%). This study highlights a need for improving screening education and uptake in Zimbabwe. Moreover, the current data provides a dataset for understanding cervical cancer pathogenesis and treatment responses in an African cohort. |
